These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32383524)

  • 41. Generation and Characterization of Patient-Derived Head and Neck, Oral, and Esophageal Cancer Organoids.
    Karakasheva TA; Kijima T; Shimonosono M; Maekawa H; Sahu V; Gabre JT; Cruz-Acuña R; Giroux V; Sangwan V; Whelan KA; Natsugoe S; Yoon AJ; Philipone E; Klein-Szanto AJ; Ginsberg GG; Falk GW; Abrams JA; Que J; Basu D; Ferri L; Diehl JA; Bass AJ; Wang TC; Rustgi AK; Nakagawa H
    Curr Protoc Stem Cell Biol; 2020 Jun; 53(1):e109. PubMed ID: 32294323
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What role could organoids play in the personalization of cancer treatment?
    Francies HE; Garnett MJ
    Pharmacogenomics; 2015; 16(14):1523-6. PubMed ID: 26485224
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Organoid technology and applications in cancer research.
    Xu H; Lyu X; Yi M; Zhao W; Song Y; Wu K
    J Hematol Oncol; 2018 Sep; 11(1):116. PubMed ID: 30219074
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Organoids for Drug Discovery and Personalized Medicine.
    Takahashi T
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():447-462. PubMed ID: 30113875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 3D Culture as a Clinically Relevant Model for Personalized Medicine.
    Fong ELS; Toh TB; Yu H; Chow EK
    SLAS Technol; 2017 Jun; 22(3):245-253. PubMed ID: 28277923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study.
    Wang HM; Zhang CY; Peng KC; Chen ZX; Su JW; Li YF; Li WF; Gao QY; Zhang SL; Chen YQ; Zhou Q; Xu C; Xu CR; Wang Z; Su J; Yan HH; Zhang XC; Chen HJ; Wu YL; Yang JJ
    Cell Rep Med; 2023 Feb; 4(2):100911. PubMed ID: 36657446
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient-derived organoid models help define personalized management of gastrointestinal cancer.
    Aberle MR; Burkhart RA; Tiriac H; Olde Damink SWM; Dejong CHC; Tuveson DA; van Dam RM
    Br J Surg; 2018 Jan; 105(2):e48-e60. PubMed ID: 29341164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An emerging role for cytopathology in precision oncology.
    Pauli C; Puca L; Mosquera JM; Robinson BD; Beltran H; Rubin MA; Rao RA
    Cancer Cytopathol; 2016 Mar; 124(3):167-73. PubMed ID: 26641771
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Next-Generation Preclinical Functional Testing Models in Cancer Precision Medicine: CTC-Derived Organoids.
    Huang L; Xu Y; Wang N; Yi K; Xi X; Si H; Zhang Q; Xiang M; Rong Y; Yuan Y; Wang F
    Small Methods; 2024 Jan; 8(1):e2301009. PubMed ID: 37882328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant Models.
    Risbridger GP; Toivanen R; Taylor RA
    Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29311126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models].
    Pauli C; Moch H; Rubin MA
    Pathologe; 2017 Nov; 38(Suppl 2):160-168. PubMed ID: 28956107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy.
    Driehuis E; Kolders S; Spelier S; Lõhmussaar K; Willems SM; Devriese LA; de Bree R; de Ruiter EJ; Korving J; Begthel H; van Es JH; Geurts V; He GW; van Jaarsveld RH; Oka R; Muraro MJ; Vivié J; Zandvliet MMJM; Hendrickx APA; Iakobachvili N; Sridevi P; Kranenburg O; van Boxtel R; Kops GJPL; Tuveson DA; Peters PJ; van Oudenaarden A; Clevers H
    Cancer Discov; 2019 Jul; 9(7):852-871. PubMed ID: 31053628
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genome engineering of stem cell organoids for disease modeling.
    Sun Y; Ding Q
    Protein Cell; 2017 May; 8(5):315-327. PubMed ID: 28102490
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current experimental human tissue-derived models for prostate cancer research.
    Kato M; Sasaki T; Inoue T
    Int J Urol; 2021 Feb; 28(2):150-162. PubMed ID: 33247498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Precision medicine for advanced prostate cancer.
    Mullane SA; Van Allen EM
    Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient-derived organoids in ovarian cancer: Current research and its clinical relevance.
    Kumar S; Raina M; Tankay K; Ingle GM
    Biochem Pharmacol; 2023 Jul; 213():115589. PubMed ID: 37196684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Organoids: the new kid in cancer research.
    Narasimhan V; Das A; Pham T; Wilson K; Kong J; Ramsay R; Heriot A
    ANZ J Surg; 2019 Oct; 89(10):1189-1190. PubMed ID: 31621167
    [No Abstract]   [Full Text] [Related]  

  • 58. Organoid development in cancer genome discovery.
    Gao D; Chen Y
    Curr Opin Genet Dev; 2015 Feb; 30():42-8. PubMed ID: 25796043
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current Status of Patient-Derived Ovarian Cancer Models.
    Maru Y; Hippo Y
    Cells; 2019 May; 8(5):. PubMed ID: 31130643
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Personalized Cancer Medicine: An Organoid Approach.
    Aboulkheyr Es H; Montazeri L; Aref AR; Vosough M; Baharvand H
    Trends Biotechnol; 2018 Apr; 36(4):358-371. PubMed ID: 29366522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.